 |
|
Recommendations for Off-Label Use of Intravenously Administered Immunoglobulin Preparations
Thomas A. Ratko, PhD;
David A. Burnett, MD;
Garrett E. Foulke, MD;
Karl A. Matuszewski, MS, RPh;
Ronald A. Sacher, MD
JAMA. 1995;273(23):1865-1870.
Abstract
| |
Objective.
—To summarize consensus recommendations for off-label uses of standard intravenous immunoglobulin (IVIG), as developed by a University Hospital Consortium (UHC) Expert Panel. These findings are intended to help guide clinicians in the appropriate and efficient use of IVIG.
Participants.
—The UHC-sponsored panel included eight physicians (board certified in critical care, hematology, immunology, neurology, oncology, pediatrics, or rheumatology) and two hospital pharmacists.
Evidence.
—MEDLINE and EMBASE were searched to identify all English-language review articles (n=201) and original reports (n=1904) on IVIG (human use only, excluding editorials, letters, and comments) published between January 1982 and March 1994. Relevant original reports (250) and review articles (87) were evaluated by the first author (T.A.R.). Extracted data included laboratory and clinical findings, objective measures, or clinical impressions. The evidence quality was graded by study design according to the US Preventive Services Task Force.
Consensus Process.
—Before the panel meeting, a draft literature review and recommendations were produced by one of the authors (T.A.R.). The recommendations herein represent consensus (100% agreement) based on the published evidence.
Conclusions.
—The UHC Expert Panel made specific recommendations for 53 off-label indications and the following general recommendations: (1) Usually IVIG is indicated only if standard approaches have failed, become intolerable, or are contraindicated; (2) IVIG products should be considered therapeutically equivalent and interchangeable; (3) interproduct pharmaceutical differences should be considered with the patient's clinical and physiological status when selecting an IVIG product; and (4) currently, IVIG manufacturers cannot guarantee freedom from viral contamination in the finished product.
(JAMA. 1995;273:1865-1870)
Author Affiliations
the University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations
From the Technology Assessment Program, Clinical Practice Advancement Center, University Hospital Consortium, Oak Brook, Ill (Drs Ratko and Burnett and Mr Matuszewski); Department of Internal Medicine, University of California, Davis, School of Medicine (Dr Foulke); and Department of Laboratory Medicine, Georgetown University Medical Center, Washington, DC (Dr Sacher). A member of the panel, Laurence B. Givner, MD, has received honoraria for lectures and fees for consultation from Baxter Healthcare Corp, Glendale, Calif.
Footnotes
A complete list of the members of the University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations appears at the end of this article.
Reprint requests to the University Hospital Consortium, 2001 Spring Rd, Suite 700, Oak Brook, IL60521-1890 (Dr Ratko).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Application of Systematic Review Methodology to the Field of Nutrition
Lichtenstein et al.
J. Nutr. 2008;138:2297-2306.
ABSTRACT
| FULL TEXT
Unlabeled uses of intravenous immune globulin
Leong et al.
Am J Health Syst Pharm 2008;65:1815-1824.
ABSTRACT
| FULL TEXT
Pharmacy considerations for the use of IGIV therapy
Shah
Am J Health Syst Pharm 2005;62:S5-S11.
ABSTRACT
| FULL TEXT
Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis
Shah and Vervan
Am J Health Syst Pharm 2005;62:720-725.
ABSTRACT
| FULL TEXT
Responding to the Immunoglobulin Shortage: A Case Study
Boulis et al.
Journal of Health Politics, Policy and Law 2002;27:977-1000.
ABSTRACT
Despair of repair
Stangel and Hartung
J. Neurol. Neurosurg. Psychiatry 2002;72:1-4.
FULL TEXT
Intravenous Immunoglobulin-Related Acute Coronary Syndrome and Coronary Angiography in Idiopathic Thrombocytopenic Purpura: A Case Report and Literature Review
Crouch and Watson
ANGIOLOGY 2002;53:113-117.
ABSTRACT
Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases?
Schmaldienst et al.
Rheumatology (Oxford) 2001;40:513-521.
ABSTRACT
| FULL TEXT
Intravenous Immunoglobulin in Acute Rheumatic Fever : A Randomized Controlled Trial
Voss et al.
Circulation 2001;103:401-406.
ABSTRACT
| FULL TEXT
Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase
Bleeker et al.
Blood 2000;95:1856-1861.
ABSTRACT
| FULL TEXT
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?: No
Karussis and Abramsky
Arch Neurol 1999;56:1028-1032.
FULL TEXT
Intravenous Immune Globulin Shortage: Experience at a Large Children's Hospital
Gurwitch et al.
Pediatrics 1998;102:645-647.
FULL TEXT
Immunopharmacology: Immunomodulation and Immunotherapy
Ballow and Nelson
JAMA 1997;278:2008-2017.
ABSTRACT
Outcome Analysis and Cost Assessment in Immunologic Disorders
Stadtmauer and Cunningham-Rundles
JAMA 1997;278:2018-2023.
ABSTRACT
|
